A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra in Healthy Chinese Male Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2019
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bio-Thera Solutions
- 11 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Mar 2019.
- 11 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2018 According to a Bio-Thera Solutions media release, dosing has begun in this trial.